Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant and adjuvant dabrafenib + trametinib for stage IIIB/IIIC BRAF V600-mutant melanoma
ACTRN12613000737730Phase 2Active, not recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by Melanoma Institute Australia. Primary endpoint: Pathological response rate after neoadjuvant therapy. Started Aug 2014; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12613000737730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000737730.